SecBot SecBot

XAIR

Beyond Air, Inc.
Nasdaq· Surgical & Medical Instruments & Apparatus· Inc. DE· CIK 0001641631 Healthcare & Medical Devices
$2.19 +0.10 (+4.78%)
Oct 26 4:00 PM ET · prev $2.09
Market cap
$3.8M
Nano cap
Consensus
Buy
88% Buy or better · 8 analysts
Median target
$20.00
+813% · range $10.00–30.00
1 year
−94.7%
from $41.60 · Oct 27
30 days
−15.4%
from $2.59
52-week range
$2.09–43.80
−95% from high · low Oct 23
Avg volume 20D
36.7K
Oct 8 spike 99.9K
Short interest
62.8K
≈6.5% of shares · +5.8%
Days to cover
1.0
at average volume
Insider net
+$287.3K
3 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
11
analyzed by SecBot
SecBot read MIXED 6 reports · 90 days
Balance 2 bearish · 1 bullish · 1 mixed · 2 neutral oldest → newest, height = score
Avg score ·High conf. 3/6

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    3 insiders bought $287.3K at an average $4.63. No open-market sales. Price is 53% below their cost.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 1 trimmed or exited.

  • AnalystsBULLISH

    7 of 8 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$8.200 → −$3.300 over 90 days.

  • Short sellersSTEADY

    Short interest +5.8% to 62.8K shares. 1.0 days to cover, ≈6.5% of shares.

  • TrendDOWNTREND

    33% below its 50-day average. New closing low $2.09 on Oct 23.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
GEODE CAPITAL MANAGEMENT, LLCTRIM112,242$50.0K
VANGUARD CAPITAL MANAGEMENT LLCADD62,741$28.0K
GEODE CAPITAL MANAGEMENT, LLCDOUBLED159,443$110.0K
GROUP ONE TRADING LLCNEAR_EXIT135$93.00
JPMORGAN CHASE & COADD40$27.00
GEODE CAPITAL MANAGEMENT, LLCADD67,678$49.1K
VANGUARD GROUP INCTRIM60,437$43.9K
BANK OF AMERICA CORP /DE/TRIM68$49.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

8 analysts
Buy 88% rate it Buy or better
Strong Buy2Buy5Hold1Sell0Strong Sell0
12-month targets · 2 analysts

Price is below the lowest target. Median implies +813%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Sep 1, 2026Lake Street
INITIATE
INITIATEBuy

Insider ledger

Form 4
$287.3K
bought · 3 insiders
$0
sold · 0 insiders
−52.7%
vs their $4.63 cost
DateInsiderTypeValue
Oct 13, 2026
Lin Yi-Chien
10%+ Owner
BUY$5.8K
Oct 1, 2026
Lin Yi-Chien
10%+ Owner
BUY$43.1K
Sep 30, 2026
Lin Yi-Chien
10%+ Owner
BUY$5.4K
Sep 29, 2026
Lin Yi-Chien
10%+ Owner
BUY$8.1K
Jul 29, 2026
MOORHEAD DANIEL J
Chief Financial Officer
BUY4,340 sh
Jul 29, 2026
Goodman Robert Scott
Chief Executive Officer
BUY$200.0K
Jul 29, 2026
Goodman Robert Scott
Chief Executive Officer
BUY34,722 sh
Jul 29, 2026
Goodman Robert Scott
Chief Executive Officer
BUY34,722 sh

Earnings setup

Estimates
−$3.30
EPS estimate, this quarter
+60%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$3.30-$3.89–-$2.71+0.5%$2.3M
Next Q-$2.23-$2.94–-$1.52-0.5%$2.2M
Current FY-$26.68-$30.66–-$22.71+0.0%$8.2M
Next FY-$8.04-$9.60–-$6.47+0.0%$16.7M

Short side

FINRA· Sep 30, 2026
62,761
shares short
+5.8%
vs prior settlement
1.0
days to cover
≈6.5%
of shares outstanding
Trading halts
Aug 27, 2026Volatility PauseResumed
Jul 10, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 21, 2026 SEC
Yi-Chien Lin filed an amended Schedule 13G disclosing a passive stake of 148,000 shares (8.9%) in Beyond Air, Inc. as…
SC 13G/A — Impact 3/10
Oct 13, 2026 Insider
Lin Yi-Chien bought 2,607 shares
10%+ Owner @ $2.21 ($5.8K)
Oct 8, 2026 SEC
Beyond Air preannounced preliminary Q3 2026 revenue of $2.3M, its highest quarterly revenue ever, representing ~30%…
8-K — Impact 5/10
Oct 1, 2026 Insider
Lin Yi-Chien bought 15,393 shares
10%+ Owner @ $2.80 ($43.1K)
Sep 30, 2026 Insider
Lin Yi-Chien bought 2,000 shares
10%+ Owner @ $2.71 ($5.4K)
Sep 24, 2026 SEC
Beyond Air, Inc. entered into a formal employment agreement with CEO Robert Goodman, effective September 23, 2026…
8-K — Impact 2/10
Aug 31, 2026 Other
Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)
GARDEN CITY, N.Y., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" o
Jul 2, 2026 Event
Griebel v. Beyond Air, Inc.
Court ruling (nyed) — Docket: 2:25-cv-02969
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent

SecBot reports

11 filings · 2 press releases · 1 bullish · 5 bearish · 2 mixed · 3 neutral
All XAIR filing & press-release reports (13)